CLBCX
Price
$34.75
Change
-$0.42 (-1.19%)
Updated
Sep 6 closing price
FBALX
Price
$29.55
Change
-$0.32 (-1.07%)
Updated
Sep 6 closing price
Ad is loading...

CLBCX vs FBALX

Header iconCLBCX vs FBALX Comparison
Open Charts CLBCX vs FBALXBanner chart's image
American Funds American Balanced 529C
Price$34.75
Change-$0.42 (-1.19%)
VolumeN/A
CapitalizationN/A
Fidelity Balanced
Price$29.55
Change-$0.32 (-1.07%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
CLBCX vs FBALX Comparison Chart
Loading...
VS
CLBCX vs. FBALX commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLBCX is a Buy and FBALX is a Buy.

FUNDAMENTALS
Fundamentals
CLBCX has more cash in the bank: 228B vs. FBALX (47.9B). FBALX (1.56) and CLBCX (1.52) have matching dividends . CLBCX was incepted earlier than FBALX: CLBCX (23 years) vs FBALX (38 years). CLBCX is a more actively managed with annual turnover of: 171.00 vs. FBALX (29.00). FBALX has a lower initial minimum investment than CLBCX: FBALX (0) vs CLBCX (250). CLBCX (17.88) and FBALX (17.38) have marching annual gain over last year. FBALX (34.64) and CLBCX (33.04) have equivalent 5 years return.
CLBCXFBALXCLBCX / FBALX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence23 years38 years-
Gain YTD10.29811.90087%
Front LoadN/AN/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets228B47.9B476%
Annual Yield % from dividends1.521.5697%
Returns for 1 year17.8817.38103%
Returns for 3 years7.90-3.39-233%
Returns for 5 years33.0434.6495%
Returns for 10 years49.4835.59139%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ELMD17.110.35
+2.09%
Electromed
PGY12.550.04
+0.32%
Pagaya Technologies Ltd
CWT54.98-0.08
-0.15%
California Water Service
JKHY173.09-1.00
-0.57%
Jack Henry & Associates
COEP0.19-0.01
-4.95%
Coeptis Therapeutics Holdings